Abdominal involvement as a primary manifestation of systemic or isolated gastrointestinal vasculitis

Abstract

Systemic vasculitides can cause a wide variety of gastrointestinal manifestations (GI) ranging from mild and frequently nonspecific abdominal pains to potentially life-threatening bowel perforations. Vascular involvement in systemic vasculitides can affect any GI blood vessel, most commonly mesenteric, hepatic, or splenic arteries. Inflammatory changes affecting different layers of arterial vessel walls can lead to aneurysmatic dilatation or blood vessel occlusion with subsequent organ ischemia leading to mucosal ulcerations, GI bleeding, perforations, or bowel obstruction. While the presence of extraintestinal manifestations may aid in diagnosis, delays in making appropriate diagnoses and rapid initiation of glucocorticoid and immunosuppressive treatment can have detrimental consequences. Awareness of isolated gastrointestinal vasculitis is of particular importance as it frequently remains undiagnosed until end-stage organ damage becomes apparent. Vasculitis mimics such as vascular Ehlers-Danlos syndrome or fibromuscular dysplasia add another lay of complexity in approaching patients with suspected GI vasculitis and should always be carefully considered.

Keywords

Vasculitis / abdominal symptoms / Isolated gastrointestinal vasculitis / vasculitis mimics

References

[1] Jennette JC,Bacon PA.2012 revised international Chapel Hill consensus conference nomenclature of vasculitides.Arthritis Rheum2013;65:1-11

[2] Martins-Martinho J,Khmelinskii N,Ponte C.Localized forms of vasculitis.Curr Rheumatol Rep2021;23:49 PMCID:PMC8247627

[3] Hernández-Rodríguez J,Hoffman GS.Single-organ vasculitis.Curr Opin Rheumatol2008;20:40-6

[4] Hernández-Rodríguez J.Updating single-organ vasculitis.Curr Opin Rheumatol2012;24:38-45

[5] Salvarani C,Crowson CS.Localized vasculitis of the gastrointestinal tract: a case series.Rheumatology2010;49:1326-35

[6] Burke AP,Virmani R.Localized vasculitis of the gastrointestinal tract.Am J Surg Pathol1995;19:338-49

[7] Hernández-Rodríguez J,Rodríguez ER.Single-organ gallbladder vasculitis: characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 61 patients.Medicine2014;93:405-13 PMCID:PMC4602437

[8] Gayraud M,Le Toumelin P.the French Vasculitis Study GroupLong-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.Arthritis Rheumatism2001;44:666-75

[9] Hilhorst M,Tervaert JW.Limburg Renal RegistryProteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis.J Am Soc Nephrol2015;26:2314-27 PMCID:PMC4587702

[10] Watts RA,Mohammad AJ,Basu N.Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Nephrol Dial Transplant2015;30 Suppl 1:i14-22

[11] Unizony S,Miloslavsky EM.RAVE-ITN Research GroupClinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Ann Rheum Dis2016;75:1166-9 PMCID:PMC4908815

[12] Cabral DA,Muscal E.ARChiVe Investigators Network within the PedVas InitiativeComparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe cohort study.Arthritis Rheumatol2016;68:2514-26

[13] Jóźwiak L,Książek A.Coexistence of granulomatosis with polyangiitis (GPA) and Crohn’s disease or multiorgan manifestation of the same disease?.Reumatologia2016;54:86-90 PMCID:PMC4918050

[14] Jayne DRW,Schall TJ.ADVOCATE Study GroupAvacopan for the treatment of ANCA-associated vasculitis.N Engl J Med2021;384:599-609

[15] Walsh M,Peh CA.PEXIVAS InvestigatorsPlasma exchange and glucocorticoids in severe ANCA-associated vasculitis.N Engl J Med2020;382:622-31 PMCID:PMC7325726

[16] Karadag O.Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda.Clin Exp Rheumatol2018;36 Suppl 111:135-42.

[17] Lightfoot RW Jr,Bloch DA.The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa.Arthritis Rheum1990;33:1088-93

[18] Guillevin L,Cohen P.Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients.Medicine1995;74:238-53

[19] Stanson AW,Johnson CM.Polyarteritis nodosa: spectrum of angiographic findings.Radiographics2001;21:151-9

[20] Balow JE.Renal vasculitis.Kidney Int1985;27:954-64

[21] Levine SM,Stone JH.Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients.Am J Med2002;112:386-91

[22] Fortin PR,Watters AK,Choquette D.Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group - a review of 45 cases.J Rheumatol1995;22:78-84.

[23] Pagnoux C,Henegar C.French Vasculitis Study GroupClinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database.Arthritis Rheum2010;62:616-26

[24] Pagnoux C,Cohen P.Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis.Medicine2005;84:115-28

[25] Becker A,Elias M,Sayfan J.Duodenal necrosis as the presenting manifestation of polyarteritis nodosa.Clin Rheumatol2002;21:314-6

[26] Carpi JM, Castejón E, Masiques L, Vilar P, Antón J, Varea V. Gastrointestinal involvement in pediatric polyarteritis nodosa.J Pediatr Gastroenterol Nutr2007;44:274-8

[27] Kariv R,Gur H.Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases.Medicine2000;79:349-59

[28] NUZUM JW Jr.Polyarteritis nodosa; statistical review of one hundred seventy-five cases from the literature and report of a typical case.AMA Arch Intern Med1954;94:942-55

[29] Thorne JC,Stevens H.A case of polyarteritis presenting as abrupt onset of pancreatic insufficiency.J Rheumatol1980;7:583-6.

[30] Iuliano L,Gualdi G.Succeeding onset of hepatic, splenic, and renal infarction in polyarteritis nodosa.Am J Gastroenterol2000;95:1837-8

[31] Empen K,Engelhardt D.Successful treatment of acute liver failure due to polyarteritis nodosa.Am J Med2002;113:349-51

[32] Goritsas CP,Papadaki E,Andonopoulos AP.Intrahepatic bile duct injury and nodular regenerative hyperplasia of the liver in a patient with polyarteritis nodosa.J Hepatol1997;26:727-30

[33] Fernandes SR,Magalhães EP,Metze K.Acute cholecystitis at initial presentation of polyarteritis nodosa.Clin Rheumatol2005;24:625-7

[34] Frohnert PP.Long-term follow-up study of periarteritis nodosa.Am J Med1967;43:8-14

[35] Guillevin L,Godeau P,Wechsler B.Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients.Br J Rheumatol1988;27:258-64

[36] Guillevin L,Mahr A.Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.Arthritis Rheum2003;49:93-100

[37] Zhou Q,Ombrello AK.Early-onset stroke and vasculopathy associated with mutations in ADA2.N Engl J Med2014;370:911-20 PMCID:PMC4193683

[38] Navon Elkan P,Segel R.Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy.N Engl J Med2014;370:921-31

[39] Jee H,Baxter S.Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach.J Allergy Clin Immunol2022;149:379-87 PMCID:PMC8591146

[40] Huang Z,Nigrovic PA.Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart.Clin Immunol2020;215:108411 PMCID:PMC7387119

[41] Lee PY,Huang Y.Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).J Allergy Clin Immunol2020;145:1664-72.e10 PMCID:PMC7282972

[42] Lee PY.Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2.Front Pediatr2018;6:282 PMCID:PMC6200955

[43] Meyts I.Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment.J Clin Immunol2018;38:569-78 PMCID:PMC6061100

[44] Caorsi R,Grossi A.ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study.Ann Rheum Dis2017;76:1648-56

[45] Ombrello AK,Hoffmann PM.Treatment strategies for deficiency of adenosine deaminase 2.N Engl J Med2019;380:1582-4 PMCID:PMC7372950

[46] Liang P.Advances in the medical and surgical treatment of Takayasu arteritis.Curr Opin Rheumatol2005;17:16-24

[47] Kerr GS,Giordano J.Takayasu arteritis.Ann Intern Med1994;120:919-29

[48] Numano F.Vasa vasoritis, vasculitis and atherosclerosis.Int J Cardiol2000;75 Suppl 1:S1-8; discussion S17

[49] Moriwaki R.Takayasu arteritis: follow-up studies for 20 years.Heart Vessels Suppl1992;7:138-45

[50] Goel R,Carette S.Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America.Rheumatology2020;59:1118-27 PMCID:PMC7850097

[51] Schmidt J,Bacani AK.Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients.Mayo Clin Proc2013;88:822-30

[52] Terao C,Yoshifuji H.Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap.Arthritis Rheumatol2015;67:2226-32

[53] Sy A,Dehghan N.Vasculitis Clinical Research Consortium (VCRC)Canadian Vasculitis Network (CanVasc)Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature.Semin Arthritis Rheum2016;45:475-82 PMCID:PMC4982464

[54] Laurent C,Fain O.PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity.Sci Rep2019;9:12388 PMCID:PMC6711961

[55] Jia S,Ma J.Application progress of multiple imaging modalities in Takayasu arteritis.Int J Cardiovasc Imaging2021;37:3591-601

[56] Saadoun D,Mirault T.Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience.Circulation2012;125:813-9

[57] Alibaz-Oner F,Bayındır Ö.Biologic treatments in Takayasu’s arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab.Semin Arthritis Rheum2021;51:1224-9

[58] Mason JC.Takayasu arteritis - advances in diagnosis and management.Nat Rev Rheumatol2010;6:406-15

[59] Buttgereit F,Matteson EL.Polymyalgia rheumatica and giant cell arteritis: a systematic review.JAMA2016;315:2442-58

[60] Smetana GW.Does this patient have temporal arteritis?.JAMA2002;287:92-101

[61] Evans JM,Hunder GG.Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study.Ann Intern Med1995;122:502-7

[62] Bienvenu B,Lambert M.Groupe d’Étude Français des Artérites des gros Vaisseauxunder the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires RaresManagement of giant cell arteritis: recommendations of the French study group for large vessel vasculitis (GEFA).Rev Med Interne2016;37:154-65

[63] Sangha S,Dawoud S.Atypical large vessel vasculitis presenting with cholestatic liver abnormalities: case-based review.J Clin Rheumatol2021;27:e561-7

[64] Scola CJ,Upchurch KS.Mesenteric involvement in giant cell arteritis. An underrecognized complication?.Medicine2008;87:45-51

[65] Lee S,Moss K.Gastrointestinal symptoms and granulomatous vasculitis involving the liver in giant cell arteritis: a case report and review of the literature.Rheumatology2011;50:2316-7

[66] Heneghan MA,DeFaoite N,O’Gorman TA.Granulomatous liver disease and giant-cell arteritis.Dig Dis Sci1998;43:2164-7

[67] Stone JH,Dimonaco S.Trial of tocilizumab in giant-cell arteritis.N Engl J Med2017;377:317-28

[68] Piram M.Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge.Curr Opin Rheumatol2013;25:171-8

[69] Audemard-Verger A,Baldolli A.Impact of aging on phenotype and prognosis in IgA vasculitis.Rheumatology2021;60:4245-51

[70] Ebert EC.Gastrointestinal manifestations of Henoch-Schonlein Purpura.Dig Dis Sci2008;53:2011-9

[71] Gendreau S,Thoreau B.French Vasculitis Study GroupCharacteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract.Semin Arthritis Rheum2021;51:436-41

[72] Nossent J,Isobel Keen H,Inderjeeth C.Morbidity and mortality in adult-onset IgA vasculitis: a long-term population-based cohort study.Rheumatology2021;61:291-8

[73] Bailey M,Licht H.The effects of vasculitis on the gastrointestinal tract and liver.Gastroenterol Clin North Am1998;27:747-82

[74] Audemard-Verger A,Guillevin L,Terrier B.IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects.Autoimmun Rev2015;14:579-85

[75] Pillebout E.[Henoch-Schönlein purpura in the adult].Rev Med Interne2014;35:372-81

[76] Pillebout E,Fardet L,Verine J.Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.Nephrol Dial Transplant2011;26:2044-6

[77] Chou T,Adams A.Successful treatment of Henoch-Schönlein purpura with recurrent gastrointestinal involvement with mycophenolate mofetil: a brief report.Clin Pediatr2015;54:900-3

[78] Ferri C.Mixed cryoglobulinemia.Orphanet J Rare Dis2008;3:25 PMCID:PMC2569912

[79] Brouet JC,Danon F,Seligmann M.Biologic and clinical significance of cryoglobulins. A report of 86 cases.Am J Med1974;57:775-88

[80] Agnello V,Kaplan LM.A role for hepatitis C virus infection in type II cryoglobulinemia.N Engl J Med1992;327:1490-5

[81] Retamozo S,Bosch X.Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients.Medicine2013;92:273-84 PMCID:PMC4553974

[82] Dammacco F,Russi S.The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Clin Exp Med2016;16:233-42

[83] Ferri C,Giuggioli D.Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.Semin Arthritis Rheum2004;33:355-74

[84] De Vita S,Isola M.Preliminary classification criteria for the cryoglobulinaemic vasculitis.Ann Rheum Dis2011;70:1183-90 PMCID:PMC3103668

[85] Mukhtyar C,Cid MC.European Vasculitis Study GroupEULAR recommendations for the management of primary small and medium vessel vasculitis.Ann Rheum Dis2009;68:310-7

[86] Saadoun D,Sene D.Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.Blood2010;116:326-34

[87] Oykhman P,Aaron SL.Multiorgan failure from cryoglobulinemic vasculitis following intravenous immunoglobulin replacement therapy.J Clin Rheumatol2016;22:441-3

[88] Chen J.A contemporary review of Behcet’s syndrome.Clin Rev Allergy Immunol2021;61:363-76

[89] Meo N, Bergamo S, Vidimari P, Bonin S, Trevisan G. Analysis of diagnostic criteria in adamantiades-behçet disease: a retrospective study.Indian J Dermatol2013;58:275-7 PMCID:PMC3726872

[90] Sakane T,Suzuki N.Behçet’s disease.N Engl J Med1999;341:1284-91

[91] Lee SK,Kim TI.Differential diagnosis of intestinal Behçet’s disease and Crohn’s disease by colonoscopic findings.Endoscopy2009;41:9-16

[92] Lee CR,Cho YS.Colonoscopic findings in intestinal Behçet’s disease.Inflamm Bowel Dis2001;7:243-9

[93] Grigg EL,Katz S.Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.Gastroen Hepatol2012;8:103-12. PMCID:PMC3317507

[94] Yanai S.Biologic drugs for inflammatory bowel disease.Nihon Rinsho2017;75:403-7.

[95] Jung YS,Lee JH.Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease.Inflamm Bowel Dis2011;17:1594-602

[96] Hatemi G,Bang D.EULAR Expert CommitteeEULAR recommendations for the management of Behçet disease.Ann Rheum Dis2008;67:1656-62

[97] Green R,Kline-Rogers E.Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US registry.Pediatr Nephrol2016;31:641-50

[98] Gornik HL,Adlam D.First International Consensus on the diagnosis and management of fibromuscular dysplasia.Vasc Med2019;24:164-89

[99] Olin JW.Is fibromuscular dysplasia a single disease?.Circulation2012;126:2925-7

[100] Khoury MH.Fibromuscular dysplasia (FMD).Vasc Med2017;22:248-52

[101] Hendricks NJ,Angle JF.Is fibromuscular dysplasia underdiagnosed?.Vasc Med2014;19:363-7

[102] Nguyen N,West JK.Presentation, clinical features, and results of intervention in upper extremity fibromuscular dysplasia.J Vasc Surg2017;66:554-63

[103] Olin JW,Bacharach JM.Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American heart association.Circulation2014;129:1048-78

[104] Stanley JC,Bove EL,Fry WJ.Arterial fibrodysplasia. Histopathologic character and current etiologic concepts.Arch Surg1975;110:561-6

[105] Guill CK,Rees C,Burton EC.Fatal mesenteric fibromuscular dysplasia: a case report and review of the literature.Arch Intern Med2004;164:1148-53

[106] Kadian-Dodov D,Gustavson S.Natural history of cervical artery fibromuscular dysplasia and associated neurovascular events.Cerebrovasc Dis2018;46:33-9

[107] Heo S,Kim B,Kim J.Clinical impact of collateral circulation in patients with median arcuate ligament syndrome.Diagn Interv Radiol2018;24:181-6 PMCID:PMC6045512

[108] Cienfuegos JA,Ruiz-Canela M.Laparoscopic treatment of median arcuate ligament syndrome: analysis of long-term outcomes and predictive factors.J Gastrointest Surg2018;22:713-21

[109] Beridze N.Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications.Cardiol Rev2012;20:4-7

[110] Pepin M,Superti-Furga A.Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.N Engl J Med2000;342:673-80

[111] Masri H, Loong TH, Meurette G, Podevin J, Zinzindohoue F, Lehur PA. Bowel perforation in type IV vascular Ehlers-Danlos syndrome. A systematic review.Tech Coloproctol2018;22:333-41

[112] Driscoll SH,Machleder HI.Perforation of the superior vena cava: a complication of digital angiography in Ehlers-Danlos syndrome.AJR Am J Roentgenol1984;142:1021-2

[113] Slingenberg EJ.Complications during intravascular diagnostic manipulations in the Ehlers-Danlos syndrome.Neth J Surg1980;32:56-8.